As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
Philips and its partners aim to combine liquid biopsy with magnetic resonance imaging to enable personalized cancer treatment.
Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.
The semifinalists will receive $50,000 each to develop prototypes of their concepts for submission in the second phase of the challenge.
The collaborations aim to combine Illumina's sequencing systems with Philips' IntelliSpace Genomics platform and with IBM's Watson for Genomics, respectively.
As part of the deal, scientists from Philips' Intellispace Genomics development team will relocate to NYMC's biotechnology incubator in Westchester County.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.